1.4Alanine as the amino acid
L-alanine dissolves in the aqueous phase and contributes to the concentration of dissolved particles. An L-alanine concentration of about 5.9 mg/mL supplies the same molar concentration as 5 mg/mL glycine.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
L-alanine dissolves in the aqueous phase and contributes to the concentration of dissolved particles. An L-alanine concentration of about 5.9 mg/mL supplies the same molar concentration as 5 mg/mL glycine.
Dissolved L-histidine accepts or releases protons as the pH changes. A titration of the complete solution measures its contribution to buffer capacity at pH 3.8.
Disodium edetate complexes dissolved iron and copper ions that catalyze oxidation. Lactic acid and lactate supply the buffer capacity around pH 3.8.
Acetic acid and acetate exchange protons as acid or base enters the solution. The acid-to-salt ratio sets the pH, and their combined concentration determines how much they contribute to buffer capacity.
Nitrogen sparging reduces dissolved oxygen before filling, and a nitrogen flush displaces air from the ampoule headspace. Flame-sealed glass limits oxygen entry during storage.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A bench fixture for veterinary infiltration training pairs a silicone skin layer with an underlying transparent gel and a cartridge containing the described formulation. A syringe drives the solution through a replaceable cannula into the gel. A load cell records plunger force, and a camera records the spread of the injected fluid through the gel.
Mannitol replaces sodium chloride as the added tonicity agent in the aqueous formulation. The anesthetic salts, epinephrine, and stabilizer components retain their stated concentrations, with final pH adjusted to 3.8 ± 0.2. A freezing point osmometer measures the completed sodium chloride reference formulation first, then measures candidate mannitol formulations to establish the mannitol concentration that matches the reference osmolality.
A single batch supplies 0.50 mL, 1.00 mL, and 1.50 mL fills in identical 2 mL glass vials. Each vial uses the same stopper and crimp seal, and all fills have the same solute concentrations and initial pH. Replicate vials from each group are stored at 25 °C and sampled at 0, 7, and 28 days for epinephrine content and pH.
A dental cartridge containing the formulation fits into a bench fixture that couples its stopper to a motorized linear syringe drive. A pressure transducer sits between the cartridge outlet and a disposable cannula, with the cannula terminating in a gel test block. The drive advances the stopper at a programmed rate and records the outlet pressure and stopper travel throughout delivery.
A stirred vessel uses a temperature-compensated pH probe and separate metering pumps for dilute acid and base. The controller reads the probe after each mixing interval and delivers a small correction when the stable reading falls outside 3.6 to 4.0. After the final volume adjustment, the controller logs the stabilized pH, solution temperature, and cumulative volume added by each pump.
A liquid chromatograph with an autosampler analyzes aliquots taken from cartridges at scheduled storage intervals. A calibrated assay separates epinephrine from the local anesthetics and uses the epinephrine peak area to calculate concentration. Software associates each result with its batch, storage temperature, and elapsed storage time, then reports concentration as a percentage of the initial batch measurement.
Crystalline lidocaine hydrochloride monohydrate supplies the lidocaine hydrochloride. The weighed amount accounts for the water of crystallization and the measured assay to deliver 20 mg of lidocaine hydrochloride per milliliter on an anhydrous basis.
An aqueous concentrate contains 80 mg of articaine hydrochloride per milliliter. The concentrate supplies half the final batch volume and yields 40 mg/mL after final volume adjustment.
A vapor-compression still evaporates feedwater and condenses the purified vapor as water for injection. The water dissolves the ingredients and brings the solution to its final volume.
A calibrated glass electrode measures pH in the mixed solution. Small additions of dilute hydrochloric acid or sodium hydroxide bring the solution to pH 3.8, with a final acceptable range of 3.6 to 4.0.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
For example, when lidocaine hydrochloride is mixed with adrenaline hydrochloride the buffering capacity of the lidocaine raises the pH of the intravenous admixtures above 5.5, the maximum necessary for stability of the adrenaline, to about 6.A · US 2016/0113891 A1 · ¶ 9
Commercially available injectable formulations include articaine hydrochloride (4%) with epinephrine in an amount of 1:1000,000 (0.01 mg/ml).B · US 11,826,347 B2 · ¶ 57
All test samples were prepared by adding adrenaline to a volumetric container to give a final concentration of 0.002 mg/ml.A · US 2016/0113891 A1 · ¶ 73
The concentration of citric acid in the injectable compositions of the present invention lies in the range of 0.1-100 mM, such as for example in the range of 1-50 mM.A · US 2016/0113891 A1 · ¶ 35
The buffer complex can be obtained from the reaction mixture of boric acid, citric acid, or mixtures thereof, and a sugar alcohol, such as D-mannitol, sorbitol, and mixtures thereof.B · US 11,826,347 B2 · ¶ 34
Next citric acid was added to give a final concentration of 0.5 mg/ml and then optionally a tonicity agent of either glucose (final concentration of 50 mg/ml), glycerol (final concentration of 25 mg/ml), lactic acid (final concentration of 16 mg/ml) or NaCl (final concentration of 9 mg/ml).A · US 2016/0113891 A1 · ¶ 97
The compositions of the present invention differ from the commercial products, which are on the market today, because the commercial products comprise both adrenaline and Na-metabisulfite as a preservative or antioxidant at much higher concentration levels.A · US 2016/0113891 A1 · ¶ 31
TABLE 2 Formulation Composition Formulations (mg/g) composition Composition A B C D E F Articaine 80 80 80 80 80 80 HCl1 Sodium 9 7.5 6 4.5 — — Chloride Sodium — 1.37 1.37 4.5 1.373 1.373 Phosphate Monobasic Monohydrate Sodium — — — — — 1.413 Phosphate Dibasic Anhydrous HPMC 8.1 8.1 8.1 8.1 8.1 8.1 K100 Premium PEG400 4 4 4 4 4 4 Final pH 6.96 6.94 7.00 6.91 4.85 6.06 Viscosity 779-827 752-792 715-801 761-799 ~700 743-803 (cp) Osmolality 610 767 725 700 507 517 (mOsm/kg) 1AmoB · US 11,826,347 B2 · ¶ 70
The topical ophthalmic anesthetic composition in one embodiment is an aqueous mixture of at least about 7.5% w/v articaine, a buffer including a complex formed from boric acid and D-mannitol, sodium acetate, acetic acid, disodium edetate, and the balance water where the composition has a pH of pH 4.5 to about pH 5.0.B · US 11,826,347 B2 · ¶ 15
The solution pH was adjusted to either pH=3 or pH=4 by use of diluted NaOH/HClA · US 2016/0113891 A1 · ¶ 73
An empty cell means only that no passage was reproduced there.
The present invention relates to injectable pharmaceutical compositions showing improved storage stability.A · US 2016/0113891 A1 · ¶ 1
Adrenaline oxidizes easily and darkens slowly on exposure to air and therefore instability of current adrenaline formulations constitute a major problem during storage if this issue is not properly addressed.A · US 2016/0113891 A1 · ¶ 7
Exemplary implementations of certain embodiments of the disclosure provide methods for topically applying a topical anesthetic formulation, for example a drop, to achieve a high level of pars plana anesthesia, sufficient to permit intravitreal injection without undue discomfort to the patient.B · US 11,826,347 B2 · ¶ 2
Currently available topical ophthalmic anesthetics perform on the external ocular surface but do not penetrate well enough to produce sufficient anesthesia of the internal aspect of the eye wall.B · US 11,826,347 B2 · ¶ 6
patent.fyi, US 2026/0355153 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355153/, SHA-256 b6dc86b370f4d07dc2c19ba746447422ed3fc37a13435b8c5be12d644b63ce9b